首页> 外文期刊>Intensive and critical care nursing >Probiotics and diarrhoea management in enterally tube fed critically ill patients--what is the evidence?
【24h】

Probiotics and diarrhoea management in enterally tube fed critically ill patients--what is the evidence?

机译:危重病人肠管饲喂的益生菌和腹泻管理-有什么证据?

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The aim of this literature review is to identify the role of probiotics in the management of enteral tube feeding (ETF) diarrhoea in critically ill patients. BACKGROUND: Diarrhoea is a common gastrointestinal problem seen in ETF patients. The incidence of diarrhoea in tube fed patients varies from 2% to 68% across all patients. Despite extensive investigation, the pathogenesis surrounding ETF diarrhoea remains unclear. Evidence to support probiotics to manage ETF diarrhoea in critically ill patients remains sparse. METHOD: Literature on ETF diarrhoea and probiotics in critically ill, adult patients was reviewed from 1980 to 2010. The Cochrane Library, Pubmed, Science Direct, Medline and the Cumulative Index of Nursing and Allied Health Literature (CINAHL) electronic databases were searched using specific inclusion/exclusion criteria. Key search terms used were: enteral nutrition, diarrhoea, critical illness, probiotics, probiotic species and randomised clinical control trial (RCT). RESULTS: Four RCT papers were identified with two reporting full studies, one reporting a pilot RCT and one conference abstract reporting an RCT pilot study. A trend towards a reduction in diarrhoea incidence was observed in the probiotic groups. However, mortality associated with probiotic use in some severely and critically ill patients must caution the clinician against its use. CONCLUSION: Evidence to support probiotic use in the management of ETF diarrhoea in critically ill patients remains unclear. This paper argues that probiotics should not be administered to critically ill patients until further research has been conducted to examine the causal relationship between probiotics and mortality, irrespective of the patient's disease state or projected prophylactic benefit of probiotic administration.
机译:目的:本文献综述的目的是确定益生菌在危重患者肠管饲喂(ETF)腹泻管理中的作用。背景:腹泻是ETF患者常见的胃肠道问题。管饲患者的腹泻发生率在所有患者中从2%到68%不等。尽管进行了广泛研究,但围绕ETF腹泻的发病机制仍不清楚。支持益生菌治疗重症患者ETF腹泻的证据仍然很少。方法:回顾性分析1980年至2010年成人危重症患者的ETF腹泻和益生菌的文献。纳入/排除标准。使用的关键搜索词是:肠内营养,腹泻,重症疾病,益生菌,益生菌种类和随机临床对照试验(RCT)。结果:确定了4篇RCT论文,其中2篇报告了完整的研究,一份报告了RCT的试验性研究,而另一篇会议摘要报道了RCT的试验性研究。在益生菌组中观察到腹泻发生率降低的趋势。但是,在某些重症和重症患者中与使用益生菌有关的死亡率必须警告临床医生不要使用它。结论:尚无证据支持使用益生菌治疗重症患者的ETF腹泻。本文认为,除非进行了进一步的研究以检查益生菌与死亡率之间的因果关系,否则不应该向危重患者使用益生菌,而不论患者的疾病状况或益生菌施用的预期预防益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号